Michael Boxer, MD, on the effectiveness of fostamatinib in the maintenance of ITP responses
Michael Boxer, MD, on the effectiveness of fostamatinib in the maintenance of ITP responses
|
Loading...
Lütfen bekleyiniz...
Type
Size

İlgili Videolar

Michael Boxer, MD, on the effectiveness of fostamatinib in the maintenance of ITP responses

Michael Boxer, MD, on the effectiveness of fostamatinib in the maintenance of ITP responses

|
Michael Boxer, MD, considers broader uses for fostamatinib

Michael Boxer, MD, considers broader uses for fostamatinib

|
Investigating the Use of Fostamatinib in ITP

Investigating the Use of Fostamatinib in ITP

|
Fostamatinib and efgartigimod: novel agents in the treatment of ITP

Fostamatinib and efgartigimod: novel agents in the treatment of ITP

|
Fostamatinib as Second-Line ITP Therapy

Fostamatinib as Second-Line ITP Therapy

|
Choosing New Agents for ITP

Choosing New Agents for ITP

|
Frontline Therapy for Immune Thrombocytopenia

Frontline Therapy for Immune Thrombocytopenia

|
Dr.Gobind Rai Garg discusses the topic - Fostamatinib

Dr.Gobind Rai Garg discusses the topic - Fostamatinib

|
Fostamatinib for Lymphoma, Leukemia

Fostamatinib for Lymphoma, Leukemia

|
Fostamatinib(R788) is a prodrug of the spleen

Fostamatinib(R788) is a prodrug of the spleen

|
PropThink Interviews: Rigel Pharmaceuticals

PropThink Interviews: Rigel Pharmaceuticals

|
News Update: AstraZeneca Reaches $1.25 Billion Pact with Rigel Pharma for Arthritis Drug (AZN,RIGL)

News Update: AstraZeneca Reaches $1.25 Billion Pact with Rigel Pharma for Arthritis Drug (AZN,RIGL)

|
Sigilon Therapeutics

Sigilon Therapeutics

|
Descubren que una medicina ya en venta podría bloquear la propagación del cáncer

Descubren que una medicina ya en venta podría bloquear la propagación del cáncer

|
Copyright. All rights reserved © 2025
Rosebank, Johannesburg, South Africa